Are you experiencing unexplained weight loss, digestive problems, abdominal pain or jaundice? Don't ignore these symptoms, these may signal underlying liver issues! PIVKA-II testing helps identify hepatocellular carcinoma(HCC) risk, it’s a critical step towards early intervention through comprehensive diagnostic follow-up.

         What is PIVKA-II ？

Protein induced by Vitamin K absence or antagonist-II (PIVKA-II), also known as abnormal prothrombin, is an abnormal form of the blood-clotting protein prothrombin. Produced when vitamin K metabolism is disrupted (e.g., in liver cancer), PIVKA-II lacks gamma-carboxylation. Its elevated levels are a hallmark of hepatocellular carcinoma (HCC) and strongly correlate with tumor size, metastasis, and prognosis. Unlike AFP, PIVKA-II offers higher specificity for HCC, especially in AFP-negative cases.

          Why Choose PIVKA-II Testing ？

•Early HCC Detection: Identifies liver cancer earlier than imaging in high-risk patients. 

•Complement to AFP: Increases diagnostic accuracy when combined with alpha-fetoprotein (AFP) testing.

•Monitor Treatment Response: Tracks tumor progression or regression post-surgery/chemotherapy. 

•Predict Recurrence Risk: Rising levels signal potential cancer recurrence.

•Risk Stratification: Guides clinical decisions for cirrhosis or hepatitis patients. 

•Sample & Reliable: A quick, patient-friendly test for proactive liver health management.

          Who Should Get Tested？

•Chronic Liver Disease Patients: Cirrhosis, hepatitis B/C carriers. 

•AFP-negative HCC Suspects: When AFP results are inconclusive. 

•Post-HCC Treatment Patients:Monitoring recurrence after resection/ablation. 

•Family History of HCC: Genetic predisposition to liver cancer. 

•Unexplained Liver Dysfunction: Elevated ALT/AST with unknown cause. 

•High-risk Lifestyles: Long-term alcohol abuse or metabolic syndrome. 

•Pre-transplant Screening: Evaluating HCC risk in liver transplant candidates.  

•Vitamin K Deficiency Disorders:To rule out malignancy-linked abnormalities. 

•Surveillance Programs: Regular testing for cirrhosis/hepatitis patients.

Getein's Cares for 

PIVKA-II CLIA Platform

Getein supports your journey toward proactive liver health with precise, actionable insights!